Compare FURY & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FURY | IMMX |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.2M | 629.3M |
| IPO Year | 2011 | 2021 |
| Metric | FURY | IMMX |
|---|---|---|
| Price | $0.54 | $9.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $1.70 | ★ $19.20 |
| AVG Volume (30 Days) | 242.4K | ★ 1.5M |
| Earning Date | 08-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.46 | $1.94 |
| 52 Week High | $1.02 | $11.61 |
| Indicator | FURY | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 49.17 | 59.36 |
| Support Level | $0.51 | $7.99 |
| Resistance Level | $0.63 | $9.77 |
| Average True Range (ATR) | 0.03 | 0.74 |
| MACD | 0.00 | 0.20 |
| Stochastic Oscillator | 56.88 | 73.16 |
Fury Gold Mines Ltd is a Canadian-focused high-grade gold exploration company. The company's projects are strategically positioned in two prolific mining regions: the Eeyou Istchee James Bay Region of Quebec and the Kitikmeot Region in Nunavut. Fury Gold's project portfolio comprises the Committee Bay gold project in Nunavut, and the Eau Claire gold, Sakami gold, Elmer East gold and lithium, and Eleonore South gold projects in Quebec. Additionally, it also owns interests in the Kipawa rare earths project and has full ownership of the Zeus heavy rare earths project, both located in the Temiscamingue region of Quebec. The company operates in two reportable segments: Quebec and Nunavut.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.